Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

Benoı̂t Rousseau, Arezki K. Boukerma, Julie Henriques, Romain Cohen, Olivier Lucidarme, Christophe Borg, Christophe Tournigand, Stéfano Kim, Jean‐Baptiste Bachet, Thibault Mazard, Christophe Louvet, Benoist Chibaudel, Déwi Vernerey, Thierry André, Anne Hulin